Midatech Pharma PLC Statement regarding Price Movement (6700L)
May 01 2020 - 6:08AM
UK Regulatory
TIDMMTPH
RNS Number : 6700L
Midatech Pharma PLC
01 May 2020
1 May 2020
Midatech Pharma PLC
("Midatech" or the "Company")
Statement regarding Price Movement
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery
technology company focused on improving the bio-delivery and
bio-distribution of medicines notes the recent movement in its
share price and the Company confirms that it knows of no
operational or corporate reason for the share price move.
As noted in the Company's recent announcements on 20 April 2020
and 31 March 2020 regarding the Company's strategic review, the
Company continues in its Formal Sale Process and confirms that
there are no material updates following those announcements.
The Company expects to announce its full year results for the
year ended 31 December 2019 by the end of June 2020.
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)1235 888300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Tel: +44 (0)20 7886 2500
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Joseph Green/ Laine Yonker
Tel: (646) 653-7030/ 7035
jgreen@edisongroup.com/ lyonker@edisongroup.com
Publication on website
A copy of this announcement will be made available (subject
to certain restrictions relating to persons resident in restricted
jurisdictions) on the Company's website at www.midatechpharma.com
in accordance with Rule 26.1 of the Code by no later than 12
noon (London time) on 21 April 2020. For the avoidance of doubt,
the content of the website referred to in this announcement
is not incorporated into and does not form part of this announcement.
Disclosure requirements of the Code
Under Rule 8.3(a) of the Code, any person who is interested
in 1% or more of any class of relevant securities of an offeree
company or of any securities exchange offeror (being any offeror
other than an offeror in respect of which it has been announced
that its offer is, or is likely to be, solely in cash) must
make an Opening Position Disclosure following the commencement
of the offer period and, if later, following the announcement
in which any securities exchange offeror is first identified.
An Opening Position Disclosure must contain details of the person's
interests and short positions in, and rights to subscribe for,
any relevant securities of each of (i) the offeree company and
(ii) any securities exchange offeror(s). An Opening Position
Disclosure by a person to whom Rule 8.3(a) applies must be made
by no later than 3.30 pm (London time) on the 10th business
day following the commencement of the offer period and, if appropriate,
by no later than 3.30 pm (London time) on the 10th business
day following the announcement in which any securities exchange
offeror is first identified. Relevant persons who deal in the
relevant securities of the offeree company or of a securities
exchange offeror prior to the deadline for making an Opening
Position Disclosure must instead make a Dealing Disclosure.
Under Rule 8.3(b) of the Code, any person who is, or becomes,
interested in 1% or more of any class of relevant securities
of the offeree company or of any securities exchange offeror
must make a Dealing Disclosure if the person deals in any relevant
securities of the offeree company or of any securities exchange
offeror. A Dealing Disclosure must contain details of the dealing
concerned and of the person's interests and short positions
in, and rights to subscribe for, any relevant securities of
each of (i) the offeree company and (ii) any securities exchange
offeror(s), save to the extent that these details have previously
been disclosed under Rule 8. A Dealing Disclosure by a person
to whom Rule 8.3(b) applies must be made by no later than 3.30
pm (London time) on the business day following the date of the
relevant dealing.
If two or more persons act together pursuant to an agreement
or understanding, whether formal or informal, to acquire or
control an interest in relevant securities of an offeree company
or a securities exchange offeror, they will be deemed to be
a single person for the purpose of Rule 8.3.
Opening Position Disclosures must also be made by the offeree
company and by any offeror and Dealing Disclosures must also
be made by the offeree company, by any offeror and by any persons
acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).
Details of the offeree and offeror companies in respect of whose
relevant securities Opening Position Disclosures and Dealing
Disclosures must be made can be found in the Disclosure Table
on the Takeover Panel's website at www.thetakeoverpanel.org.uk,
including details of the number of relevant securities in issue,
when the offer period commenced and when any offeror was first
identified. You should contact the Takeover Panel's Market Surveillance
Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether
you are required to make an Opening Position Disclosure or a
Dealing Disclosure.
Additional information
Panmure Gordon (UK) Limited ("Panmure"), is authorised and regulated
by the Financial Conduct Authority in the United Kingdom. Panmure
is acting as financial adviser in relation to the Takeover Code
exclusively for M idatech and no one else in connection with
the matters set out in this announcement and will not regard
any other person as its client in relation to the matters set
out in this announcement and will not be responsible to anyone
other than Midatech for providing the protections afforded to
clients of Panmure or its affiliates, or for providing advice
in relation to the contents of this announcement or any other
matter referred to herein.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
SPMSSMFSFESSESI
(END) Dow Jones Newswires
May 01, 2020 06:08 ET (10:08 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Jul 2023 to Jul 2024